Overview
- Analyzing 3,884 participants aged 70 and older, the cohort found vaccinated adults showed lower systemic inflammation, slower epigenetic and transcriptomic aging, and a reduced composite biological‑aging score.
- Benefits were time‑dependent, with epigenetic and transcriptomic signals most pronounced within roughly three years of vaccination and inflammation and innate‑immune changes emerging after about four years or more.
- The study detected no significant associations with neurodegeneration biomarkers or cardiovascular hemodynamic measures, and adaptive‑immunity scores were higher in vaccinated adults, a result the authors attribute to biomarker limitations.
- Because most vaccinations occurred before 2017, the findings primarily reflect the older live‑attenuated Zostavax, and the researchers say the newer Shingrix formulation needs evaluation.
- The authors emphasize the observational nature of the results and call for longitudinal and causal studies, noting the work aligns with emerging evidence that some adult vaccines may influence aging‑related biology.